Pioglitazone HCl / Pioglitazone Hydrochloride CAS 112529-15-4
Product Description
| Prodcut name | PIOGLITAZONE HYDROCHLORIDE |
| MOQ | 1kg |
| CAS No. | 112529-15-4 |
| Appearance | crystalline powder |
| Molecular Formul | C19H21ClN2O3S |
| Assay | 99% |
| Application | Pharma grade or research purpose |
| Storage | Preserve in tight, light-resistant containers in a cool place |
| Custom synthesis | Available |
| Supply Ability | 500kg/month |
Pioglitazone is a new orally active thiazolidinedione (TZD) launched in the US for the treatment of dependent diabetes mellitus (NIDDM). As with other representatives in this class, it potently activates the nuclear receptor peroxisome proliferator-activated receptor gamma which is believed to be involved in the regulation of resistance and adipogenesis. In several obese and obese diabetic animal models, treatment with Pioglitazone resulted in reductions in plasma glucose and serum lipids. In clinical studies, Pioglitazone at a once daily oral dose of 15-45 mg, as monotherapy or in combination with non-TZDs , was shown to significantly improve glycemic control in type-2 diabetes and demonstrated a beneficial effect on resistance and other clinically relevant parameters as plasma levels of triglycerides or HDL-cholesterol. Pioglitazone is reported to be safe and well tolerated and is said to have a lower occurrence of hepatic toxicity as well as a low probability for drug interaction.
